T1	Participants 56 89	extensive small-cell lung cancer:
T2	Participants 287 378	previously untreated patients with extensive-stage small-cell carcinoma of the lung (SCLC).
T3	Participants 400 546	Patients with extensive SCLC with a Karnofsky performance score (KPS) > or = 50 and adequate renal function and bone marrow reserve were eligible.
T4	Participants 547 589	Patients with CNS metastases were eligible
T5	Participants 946 1034	From May 1989 through March 1993, 171 patients were randomized (84 to VP and 87 to VIP).
T6	Participants 1079 1182	All patients were assessable for survival; 163 were fully assessable for response and 162 for toxicity.
T7	Participants 1804 1833	patients with extensive SCLC.
